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Abstract
Human 2-oxoglutarate oxygenases catalyse a range of biological oxidations including the demethylation of histone and
nucleic acid substrates and the hydroxylation of proteins and small molecules. Some of these processes are centrally
involved in regulation of cellular responses to hypoxia. The ALKBH proteins are a sub-family of 2OG oxygenases that are
defined by homology to the Escherichia coli DNA-methylation repair enzyme AlkB. Here we report evidence that ALKBH5 is
probably unique amongst the ALKBH genes in being a direct transcriptional target of hypoxia inducible factor-1 (HIF-1) and
is induced by hypoxia in a range of cell types. We show that purified recombinant ALKBH5 is a bona fide 2OG oxygenase
that catalyses the decarboxylation of 2OG but appears to have different prime substrate requirements from those so far
defined for other ALKBH family members. Our findings define a new class of HIF-transcriptional target gene and suggest
that ALKBH5 may have a role in the regulation of cellular responses to hypoxia.
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Introduction
Recent work has revealed an extensive family of Fe(II) and 2-
oxoglutarate (2OG) dependent oxygenases encoded in the human
genome (reviewed in [1]). Some, for instance the HIF hydroxy-
lases, are involved in the cellular response to hypoxia [2]; Other
family members have diverse functions, including fatty acid
metabolism, histone demethylation, and DNA repair [1,3,4,5].
Human homologues of the Escherichia coli DNA repair enzyme
AlkB are termed ALKBH enzymes. Some ALKBH enzymes have
been demonstrated to function as nucleic acid demethylases,
catalyzing the oxidative demethylation of 1-methyladenine and 3-
methylcytosine in DNA and RNA [3,6,7]. Eight human AlkB
homologues (ALKBH1-8) have been predicted, of which three
(ALKBH1-3) have been shown to exhibit nucleic acid demethyl-
ation activity [8,9,10]. Additionally, a DNA lyase activity has been
recently described for ALKBH1 that is Fe(II) and 2OG
independent [11]. ALKBH8 expression has been implicated in
bladder cancer progression. Recently, a tRNA methyltransferase
activity of ALKBH8 has been described and implicated in
translational decoding [12,13,14].
Several 2OG oxygenases, including two of the HIF hydroxy-
lases themselves, and more recently, several of the JmjC domain-
containing histone demethylases (JMJDs), have been identified as
hypoxia-inducible gene products [15,16,17,18,19,20,21,22,23].
In order to test whether human 2OG oxygenases acting, or
potentially acting, on nucleic acids are regulated by hypoxia, we
compared the expression of ALBKH genes in normoxic and
hypoxic conditions and identified ALKBH5 to be induced by
hypoxia. Analysis of the ALKBH5 promoter in silico identified two
putative HIF binding sites. Through chromatin precipitation
studies we demonstrate that one of these sites binds HIF-1a.
Analysis of cell lines bearing genetic interventions on the HIF
pathway, confirm that ALKBH5 is a novel HIF-1a responsive gene.
Results and Discussion
ALKBH5 is a hypoxia-induced gene
To determine the extent of regulation by hypoxia among the
human ALKBH family, we exposed a series of cell lines to hypoxia
and tested for alterations in transcript levels by RT-Q-PCR across
all ALKBH family members. The results shown in Figure 1a reveal
a consistent pattern of regulation by hypoxia. ALKBH5 was
consistently up regulated in response to hypoxia (.2-fold in
MCF7, U2OS and IMR32 cells), whereas none of the other
ALKBH genes showed significant changes in expression. To
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Figure 1. Hypoxia upregulates ALKBH5 via HIF-1a. (A) Hypoxic induction of ALKBH1-8 in MCF7, U2OS and IMR32 cells. Values are the fold
increase in mRNA in cells cultured for 16 hours in hypoxia (1.0% oxygen) relative to parallel cultures in normoxia (21% oxygen). Only ALKBH5 is
significantly upregulated (p,0.01) in each cell type. (B)(i) ALKBH5 mRNA was significantly induced in MCF7, U2OS and IMR32 cells by hypoxia (1.0%
oxygen for 16 hours) and DMOG (1 mM for 16 hours). (ii) Immunoblot demonstrating increased protein levels of HIF-1a (top panel) and ALKBH5
(middle panel) under hypoxia and DMOG treatment. Protein loading is indicated by b-actin signal (bottom panel). (C) Genetic manipulation of the
HIF/VHL system in normoxia modulates ALKBH5 expression. Inducible HIF-1a overexpression in U2OS cells and subsequent RT-Q-PCR analysis (i)
shows a significant increase in ALKBH5 mRNA after doxycycline administration. Expression of VHL in RCC4 cells and subsequent RT-Q-PCR analysis (ii)
shows significant decrease in ALKBH5 mRNA by 48 hours after doxycycline administration. Inducible peptide blockade of HIF-1a degradation
demonstrating increased expression of HIF-1a protein (iii) at 24 hours (lane 2) and 48 hours (lane 3). RT-Q-PCR analysis (iv) shows a significant
(p,0.01) increase in ALKBH5 mRNA after doxycycline administration. RT-Q-PCR analysis (v) demonstrates significant reduction in hypoxic induction of
ALKBH5 mRNA by HIF-1a directed siRNA. These changes were not observed in siRNA directed against Drosophila HIFa or human HIF-2a. Knockdown
for each HIFa subunit was greater than 90% as confirmed by both RT-Q-PCR and immunoblotting (data not shown). (D) HIF-1a binds the 2482 to
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determine whether induction by hypoxia was mediated by HIF
hydroxylase pathways we next compared the action of hypoxia
with that of dimethyl oxalylglycine (DMOG), a cell penetrating,
generic 2OG oxygenase inhibitor. The results for MCF7, U2OS
and IMR32 cells (Figure 1Bi) and reveal very similar patterns of
mRNA induction to those observed following exposure of cells to
hypoxia and DMOG, for ALKBH5. In line with the observed
increase in ALKBH5 mRNA levels, immunoblotting of cell extracts
revealed that ALKBH5 protein levels were also increased
substantially, both in hypoxic conditions and after DMOG
treatment (Figure 1Bii). To further explore the dependence of
ALKBH5 induction on the HIF system, we measured changes in
ALKBH5 mRNA in a series of cell lines in which we were able to
manipulate HIF in normoxic conditions (Figure 1C). Doxycycline-
mediated induction of HIF-1a, either directly in U2OS transfec-
tants bearing an inducible HIF-1a transgene, or indirectly in
U2OS transfectants expressing a peptide encompassing the HIF-
1a C-terminal prolyl hydroxylation site that blocks degradation of
the native HIF-1a molecule, resulted in sustained induction of
ALKBH5 mRNA (Figure 1Ci,iii,iv). Conversely, doxycycline-
mediated re-expression of HA-tagged wild-type VHL transgene
into VHL-defective RCC4 cells [24] reduced ALKBH5 mRNA
levels, in line with restoration of VHL-mediated degradation of
HIF (Figure 1Cii). Finally, we tested the role of HIF-1a and HIF-
2a isoforms using siRNA mediated knockdown in hypoxic MCF7
cells. As indicated in (Figure 1Cv) siRNA directed against HIF-1a
substantially reduced expression of ALKBH5 whereas siRNA
directed against HIF-2a resulted in a modest, but statistically
insignificant increase, of ALKBH5 mRNA. These results indicate
that induction of ALKBH5 by hypoxia is mediated directly or
indirectly by HIF-1a.
Bioinformatic analysis of the ALKBH5 locus revealed two
putative hypoxia-response elements (59-RCGTG-39) at 2486/
2482 (herein termed HRE A) and +265/+269 (herein termed
HRE B), referenced to the transcriptional start site (Supplemen-
tary figure S1). Both HIF binding sites displayed high conservation
across other vertebrate genomes, suggesting functional conserva-
tion (Supplementary figure S1). Therefore, we carried out both
chromatin immunoprecipitation (ChIP) and luciferase reporter
assays to test whether ALKBH5 is a direct HIF transcriptional
target gene (Figure 1D,E). DNA from MCF7 cells was precipitated
using anti-HIF-1a antibodies (PM14) or anti-HIF-2a antibodies
(PM9) or control, pre-immune sera; precipitated DNA was subject
to RT-Q-PCR analysis using primers designed to amplify each of
the predicted HREs. Significant and reproducible enrichment of
DNA containing HRE A at the ALKBH5 locus was observed with
anti-HIF-1a (.18-fold), but not anti-HIF-2a antibodies
(Figure 1Dii). In contrast, no enrichment was observed at HRE
B with either anti-HIF-1a or anti-HIF-2a. The ability of HIF-1a
to bind the ALKBH5 promoter in different cell lines was confirmed
by ChIP in the renal cancer cell lines CAKI (Figure 1Diii) and
RCC4 (Figure 1Div). Finally, a promoter fragment containing the
ALKBH5 HRE A was sufficient to drive hypoxia inducible
expression of a luciferase reporter gene (Figure 1E) in HeLa cells
at a comparable level to that seen with the promoter of a known
HIF-target gene, carbonic anhydrase IX (CAIX) [25].
ALKBH5 is a 2OG Oxygenase
To investigate whether ALKBH5 encodes an active 2OG
oxygenase, we prepared purified recombinant ALKBH5 and tested
the protein for catalytic activity in assays for 2OG decarboxylation.
An N-terminal truncated protein, ALKBH566–292, was produced in
a soluble recombinant form in E. coli and was purified to near
homogeneity, as assessed by SDS-PAGE analysis. Based on the
knowledge that many 2OG oxygenases can oxidise 2OG to CO2
and succinate in the absence of their prime substrate, we employed
an assay for ALKBH5 that measures the conversion of 1-[14C]-
2OG to succinate and [14C]-CO2. These assays demonstrated that
ALKBH5 stimulated 2OG decarboxylation in a manner that was
dependent on supplementation with the 2OG oxygenase co-factors,
Fe(II) and ascorbate, and inhibited by the 2OG oxygenase inhibitor
pyridine-2,4-dicarboxylate (2,4-PDCA) thus indicating that
ALKBH5 is an active 2OG oxygenase (Figure 2A). Increased
transcription of the HIF prolyl hydroxylases (PHD2 and 3) is
observed in hypoxia and has been proposed to compensate for the
reduction in enzymatic activity and modulate hypoxia signaling
[26]. Therefore, to further investigate the functional significance of
hypoxic induction of ALKBH5, we analysed the effect of different
oxygen levels (21%, 5.0% and 1.0%) on ALKBH5 activity
(Figure 2B). Enzyme activity was reduced up to 75% at 5.0%
oxygen and virtually absent at 1.0% oxygen (Figure 2B). It is
therefore possible that upregulation of ALKBH5 in hypoxia
compensates, at least in part, for the reduced enzymatic activity.
Given that among ALKBH family members, induction by hypoxia
appears to be strictly confined to ALKBH5 this might indicate that
the enzyme has some specific function in hypoxic cells and it would
be of interest to determine the correlation between ALKBH5
expression and oxygen levels in normal and neoplastic mammalian
cells and tissues. To investigate whether ALKBH5 possesses DNA
demethylase or DNA hydroxylase activity against known substrates
for this class of enzymes, we prepared a set of 18-mer single-
stranded oligonucleotides containing modified bases including 1-
methyladenine (1meA), 3-methylcytosine (3meC), 5-methylcytosine
(5meC), 1-methylguanine (1meG) and 3-methylthymine (3meT) by
solid-phase oligonucleotide synthesis. However, none of these
potential substrates significantly increased ALKBH5-mediated
2OG turnover and none were converted to demethylated or
hydroxylated products, as indicated by LC-MS analysis (Figure 2C,
D, Supplementary figure S2). Whilst we cannot rule out the
possibility that full-length post-translationally modified ALKBH5
may act on these or other substrates, the observation that under in
vitro conditions ALKBH5 does catalyze 2OG turnover but did not
result in chemical modification of the tested potential substrates
argues against this. With this caveat, our results suggest that either
ALKBH5 does not act on these modifications, or only does so in a
different context.
Cellular localisation and potential role in DNA repair of
ALKBH5
To further investigate a potential role for ALKBH5 in nucleic
acid metabolism, we characterised its cellular localization.
Previously, N-terminally (GFP)-tagged ALKBH5 has been shown
2486 promoter region of the ALKBH5 gene and mediates hypoxic induction of a luciferase reporter in MCF7 cells. (i) Figure indicating 2 putative HREs
(A,B) and their relative positions to the transcriptional and translational start sites. (ii) DNA encompassing HRE A was significantly enriched in
chromatin precipitated with PM14 (anti-HIF-1a) but not with pre-immune sera (PS) or PM9 (anti-HIF-2a) in both (iii) CAKI-1 and (iv) RCC4 renal cancer
cells. No enrichment was observed in DNA encompassing HRE B. (E) MCF7 cells were transfected with pGL3promoter vectors expressing the putative
ALKBH5 HRE A sequence. pGL3promoter vectors that were either ‘‘empty’’ or contained the CA9 HRE served as controls as did an ‘‘irrelevant’’ vector.
Luciferase activities were normalized to those of b-galactosidase in each sample. Luciferase activity was significantly increased after 16 hours of
DMOG (1 mM) treatment in cells expressing pGL3-CA9 and pGL3-ALKBH5[HRE A] but not in the control plasmid or ‘‘empty vector.
doi:10.1371/journal.pone.0016210.g001
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to localise throughout the cell [27]. Firstly, we verified that our
antibody was specific to endogenous ALKBH5 and therefore
sensitive to decreased levels of ALKBH5 in cultured cells. In
keeping with this ALKBH5 immunoreactivity was substantially
suppressed in U2OS cells treated with siRNA against ALKBH5 in
comparison with that treated with a scrambled (control) siRNA
(Figure 3A(i)). Next, U2OS cells were stained with anti-ALKBH5
(shown in red) and 49,6-diamidino-2-phenylindole (DAPI) as a
nuclear marker (shown in blue) (Figure 3A(ii)). We observed almost
complete loss of nuclear staining when employing the siRNA
directed against ALKBH5 (Figure 3A(ii)). Furthermore, Taqman
RT-Q-PCR analysis confirmed a .10-fold reduction of ALKBH5
at the mRNA level but no changes in mRNA levels of ALKBH1,-
2,-3,-4, -6,-7 or -8 (data not shown). Our data shows that
endogenous ALKBH5 resides predominantly in the nucleus with
only sparse cytoplasmic staining. Immunohistochemical staining of
human tissues (Figure 3B) indicates that ALKBH5 also localises
primarily to the nucleus in vivo.
Severe hypoxia induces a DNA damage response which includes
both ataxia telangiectasia and Rad3 related/ataxia telangiectasia
mutated (ATR/ATM) activation [28,29]. The hypoxia-induced
DNA damage response is unusual in that DNA damage is not
detected by either comet assay or tumor protein p53 binding protein
1 (53BP1) foci formation, but histone H2AX is phosphorylated (to
form foci of cH2AX) [30]. More recently, depletion of dNTPs in
these hypoxic conditions was shown to lead to the stalling of
replication forks which in turn initiates a DNA damage response
[31]. In contrast to hypoxia, reoxygenation has been shown to
induce significant levels of ROS-dependent DNA damage [32].
Given that ALKBH5 is a HIF-induced nuclear protein with a
possible role in DNA repair (based on homology to E.coli AlkB), we
investigated a potential role for ALKBH5 in the context of DNA
damage/repair under conditions of hypoxia/reoxygenation. Com-
parison of U2OS cells treated with ALKBH5 siRNA or a scrambled
(control) siRNA allowed us to analyse the ALKB5-dependence of
the response to hypoxia/reoxygenation by assessing cH2AX and
53BP1 foci formation (Supplementary Figure S3). siRNA knock
downs were validated by RT-Q-PCR and were at least 90%
efficient (data not shown). In each case the numbers of cells
containing more than 10 nuclear foci were scored. The levels of
Figure 2. ALKBH5 displays biochemical characteristics of a functional 2OG-dependent oxygenase in vitro. (A) Enzyme-dependent
stimulation of uncoupled turnover that was dependent on the cofactors ascorbate, and Fe(II) and inhibited by 1 mM of the generic 2OG oxygenase
inhibitor pyridine-2,4-dicarboxylate (2,4-PDCA). (B) Enzyme-dependent stimulation of uncoupled 2OG turnover that was sensitive to the oxygen
concentration. Turnover was significantly reduced under moderate hypoxia (5.0% oxygen) and negated under more severe hypoxia (1.0%) (C) Testing
of potential oligonucleotide substrates; 1-methylguanine (1meG) 3-methylthymine (3meT) and (D) 1-methyladenine (1meA), 3-methylcytosine
(3meC), 5-methylcytosine (5meC). No significant increase in ALKBH5 activity was observed in the presence of methylated oligonucleotides.
doi:10.1371/journal.pone.0016210.g002
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cH2AX increased during hypoxia and persisted for at least 8 hours
after reoxygenation. In contrast, as previously shown [30], 53BP1
did not form foci until reoxygenation. In each case the loss of
ALKBH5 did not affect the response indicating that the
components of the DNA damage response and repair are not
dependent on ALKBH5 levels. We then extended these studies to
consider if loss of ALKBH5 during hypoxia/reoxygenation affects
cell survival by carrying out clonogenic survival assays (Supplemen-
tary Figure S3). Loss of ALKBH5 did not affect cell survival after
hypoxia/reoxygenation indicating that hypoxia-induced ALKBH5
does not have an essential role in this process. As a final test, we
carried out a second clonogenic survival experiment in moderate
hypoxic (2% O2) conditions with the addition of c-irradiation. The
c-irradiations were carried out under hypoxic conditions (2% O2)
but cells were returned to normal culture conditions 30 minutes
after irradiation (Supplementary Figure S3). Again, no effect of loss
of ALKBH5 was determined. Together, these data indicate that
hypoxia-induced ALKBH5 does not have a role to play in DNA
repair or the DNA damage response.
Conclusions
Taken together our studies identify ALKBH5 as a 2OG
dependent oxygenase that is inducible by hypoxia through the
action of HIF-1a. Induction of ALKBH5 by HIF-1a was unique
amongst the known ALKBH family members suggesting a specific
role for ALKBH5 in the response to hypoxia, as has recently been
postulated for other 2OG dependent oxygenases that modulate
patterns of histone methylation in hypoxic cells [20]. Though
ALKBH5 is largely confined to the nucleus in human cancer cells
we have not yet clearly defined its function. Its substrate(s)
requirements also appear to be different from those so far defined
for other ALKBH family members. Nevertheless our demonstra-
tion that recombinant ALKBH5 supports the uncoupled decar-
boxylation of 2OG in a manner that is co-factor and inhibitor
dependent clearly assigns the protein as a functional 2OG
oxygenase and should enable further physiological analysis.
Materials and Methods
Cell culture
Human osteosarcoma (U2OS), breast cancer (MCF7), hepatoma
(HEP3B) and cervical carcinoma (HeLa) cells were cultured in
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen) supple-
mented with 10% (v/v) fetal calf serum (FCS) (Sigma). Human
neuroblastoma cells (IMR32) were cultured in Eagle’s minimal
essential medium (Invitrogen) with 10% (v/v) FCS, 2mM glutamine
(Invitrogen) and non-essential amino acids. All cells were main-
tained in a humidified atmosphere of 5%CO2 and 21%O2. U2OS,
HeLa, MCF7, HEP3B and IMR32 cells were obtained from
Cancer Research UK. R38 (human renal carcinoma (RCC4) cells
that express a tetracycline-inducible hemagglutinin (HA)-tagged
von Hippel-Lindau (VHL) transgene), C29 (U2OS cells expressing
tetracycline inducible HIF-1a) and myc19 (U2OS cells expressing a
tetracycline inducible c-myc-tagged HIF-1a peptide (residues 549–
582) have been previously described [24,33] and were cultured in
DMEM with 10% (v/v) tetracycline-free FCS (BD Bioscience)
supplemented with 1 mg/ml G418 and 5 mg/ml Blasticidin (Sigma).
In the experimental work, cells were cultured under normoxic
conditions (5% CO2, 21% O2), in moderate hypoxia (16 hours at
5% CO2, 0.5–2% O2, Invivo2 hypoxia workstation), or severe
hypoxia (16 hours at 0.02% O2, Bactron chamber, Shel Lab).
Where specified, cells were treated with dimethyloxalyl glycine
(DMOG) (1mM for 16 hours).
siRNA Treatment of Cells and clonogenic survival assays
MCF7 and U2OS cells were seeded at 30% confluency and
grown in normoxic conditions. Cells were transfected twice at
24 hour intervals with siRNA (20nM) using Oligofectamine
(Invitrogen) according to the manufacturer’s protocol. The siRNA
oligonucleotide sequences used for HIF-1a and HIF-2a were as
described [34]. For survival assays, U2OS cells were treated with
siRNA as above, exposed to hypoxia (0.02% O2) for the times
indicated, and then returned to normal culture conditions to form
Figure 3. ALKBH5 localizes predominantly to the nucleus. (A)(i) Immunoblot demonstrating protein levels of ALKBH5. U2OS cells were
treated with either a scrambled (control) siRNA sequence (left lane) or siRNA directed against ALKBH5 (right lane). Protein loading is indicated by b-
actin. (ii) Immunofluorescence-based detection of ALKBH5 protein in U2OS cells treated with either a scrambled (control) siRNA sequence (top panel)
or siRNA directed against ALKBH5 (bottom panel). (B) Nuclear ALKBH5 expression in normal breast, skin, testis and kidney. Original magnifications
6400.
doi:10.1371/journal.pone.0016210.g003
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colonies (approx 10 days) which were then stained with crystal
violet.
RNA Extraction and cDNA Synthesis
Total RNA was extracted using the Sigma Total RNA kit
(Sigma) according to the manufacturer’s protocol. First strand
cDNA synthesis was generated from 5 mg of total RNA (GE
Healthcare).
Protein Extraction and Immunoblot Analysis
Preparation of cell extracts and immunoblot analyses were
performed as described [35]. Primary antibodies used were mouse
anti-HIF-1a (BD Transduction Laboratories), rabbit anti-HIF-2a
(Novus Biologicals), rabbit anti-ALKBH5 (Sigma), mouse horse-
radish peroxidase (HRP)-conjugated anti-HA (Dako), rabbit
phospho-H2AX (Abcam), mouse anti-b-actin (Santa Cruz) and
mouse HRP-conjugated anti-b-actin (Abcam).
Immunofluorescence
Transiently transfected U2OS cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) for
15 min, permeabilized in Triton X-100 (0.05% in PBS) and
stained with anti-ALKBH5 (Sigma), anti-53BP1 (Novus Biologi-
cals) or anti-cH2AX (Upstate). Secondary antibodies were anti-
rabbit-alexa-fluor-594 or anti-mouse-alexa-fluor-594 (Invitrogen).
Cells were counterstained with 4,6-diamino-2-phenylindole
(DAPI) fluorescent dye (Vector Laboratories), as a nuclear marker.
Immunohistochemistry
Immunohistochemistry was carried out as described [36] using
the EnVision kit (Dako) and rabbit anti-ALKBH5 (Sigma).
Chromatin Immunoprecipitation (ChIP) Assays
DNA-binding proteins were cross-linked to DNA using
formaldehyde at a final concentration of 1% (w/v) for 10 minutes
at 25uC, followed by treatment with glycine (125 mM) for a
further 5 minutes. Cells were washed in PBS, lysed in SDS lysis
buffer, and sonicated (Sonics & Materials, VCX 500). The
supernatant was collected by centrifugation and pre-cleared with
protein A agarose beads (Millipore). Chromatin was then
incubated overnight with rabbit polyclonal anti-sera to HIF-1a
(PM14) and HIF-2a (PM9) [37] before adding protein A agarose
for a further hour. Pre-immune serum was used as a negative
control. The beads were washed and immunoprecipitated
complexes were eluted into 1% SDS, 0.1 M sodium bicarbonate
elution buffer. Cross-linking was reversed by overnight incubation
at 65uC and followed by protein digestion with proteinase K. DNA
was recovered by phenol/chloroform extraction and ethanol
precipitation.
Real-time quantitative PCR
RT-Q-PCR for mRNA quantification employed Taqman gene
expression assays on a StepOne thermocycler (Applied Biosys-
tems). Normalization was to HPRT1 mRNA and relative gene
expression was calculated using the DDCT method. A cDNA
template of 10 ng per reaction was used and 3 biological
replicates, each in triplicate, were performed for each experiment.
For quantification of HIF binding sites, ChIP DNA (5 ng) from
each of input, preimmune sera, PM14 and PM9 was subject to
RT-Q-PCR using oligonucleotides designed to amplify putative
HRE consensus sequences (Supplementary Figure S1). Fold
enrichment was determined by the DDCT method. Statistical
comparisons were performed using Student’s unpaired t-test.
Luciferase Reporter Assays
Cells at 70% confluence in 6-well plates were transfected with
the specified ALKBH5 luciferase reporter plasmid (0.5 mg),
together with pRSV b-galactosidase control plasmid (0.1 mg).
Luciferase assays were performed 36 h post-transfection with a
luminometer; relative luciferase light units were normalized to b-
galactosidase activity.
Expression plasmids and protein purification
For production in E. coli, a human ALKBH5 cDNA encoding an
N-terminal His6-tag linked to residues 66-292 was inserted into the
pNIC28-Bsa4 expression vector. For large-scale ALKBH5 pro-
duction, plasmids were transformed into E. coli Rosetta 2 (DE3)
cells, induced with 0.5 mM IPTG at OD 0.6 and grown for
16 hours at 18uC. Cells were harvested and lysed by sonication in
20 mM Tris-HCl (pH 7.9), 0.5 M NaCl, 5 mM imidazole and
10 mM MgCl2 in the presence of DNAse and protease inhibitor
cocktail (Roche CompleteTM Mini EDTA-free); soluble protein
was purified by immobilized Ni(II) affinity chromatography using
Ni-NTA HisBindH resin (Novagen) and subsequent gel filtration
chromatography. Protein of .95% purity (by SDS/PAGE
analysis) was exchanged into 50 mM Tris-HCl, 100 mM NaCl
(pH 7.5) buffer and concentrated for activity analyses.
Co-substrate turnover experiments
Purified recombinant ALKBH5 was tested for its ability to
stimulate ALKBH5-dependent decarboxylation of 1-[14C]-la-
belled 2OG, as described [38,39]. Standard assay conditions
comprised a total volume of 100 ml: 50 mM Tris?HCl pH 7.5,
4 mM ascorbate, 288 mM 2OG, 3.7 mM 1-[14C]-2OG (specific
activity 56.8 mCi?nmol21, stock concentration 1.83mM, Perkin
Elmer NEN), 100 mM FeSO4?7H2O, 0.66 mg?ml
21 catalase,
4 mM enzyme. Briefly, the assay was set up in three drops, one
containing enzyme (10 ml 40 mM), another containing buffer,
substrate or inhibitor (10 ml 1 mM) and the third (80 ml)
containing all other reagents prior to mixing in a 5 ml tube. A
0.5 ml Eppendorf vial containing 200 ml hyamine hydroxide was
added and the tube was then sealed with a rubber septum. The
reaction was started by mixing and incubated with shaking at
37uC for 15 minutes and then quenched with methanol (200 ml).
Reaction tubes were then kept on ice for 20 minutes, before the
hyamine hydroxide was removed and treated with scintillant liquid
for radioactive count measurement in dpm. Conversion of 2OG
was calculated from the percentage of 1-[14C]-2OG that had been
converted to 14CO2 gas. Assays were performed in triplicate. For
testing of potential substrates, the assay was performed as above,
except that mixtures comprised three drops, one containing
enzyme (10 ml 40 mM), another containing oligonucleotide (15 ml
100 mM) and the third (75 ml) containing all other reagents. The
oligonucleotide sequence used was 59-GCXAGGTCCCG-
TAGTGCG-39, where X denotes the modified base. Oligonucle-
otides were purchased from ATDBio Ltd. (Southampton, UK) or
Sigma-Aldrich and purified by desalting or reversed-phase HPLC
as required. Oligonucleotide purity was checked by MALDI or
HPLC analysis.
LCMS-based oligonucleotide turnover experiments
Potential conversion of single-stranded DNA oligonucleotides
by purified recombinant ALKBH5 was investigated using
oligonucleotide LCMS analysis based on ion pairing. Incubations
contained 5 mM enzyme, 10 mM oligonucleotide substrate, 50 mM
FeSO4.7H2O, 300 mM 2OG, 4 mM sodium ascorbate and,
optionally, 300 mM pyridine-2,4-dicarboxylic acid in a total
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volume of 50 ml with 50 mM Tris pH 7.5. Samples were
incubated overnight at 37uC with shaking. The reactions were
stopped by addition of 100 ml CH3CN, incubated on ice for
1 hour and centrifuged at 14,000 rpm for 10 minutes at 4uC. The
supernatant was lyophilised and reconstituted in ultrapure water.
Samples (10 ml) were run on a 2.5 mm Waters XBridge OST C18
Column (4.6650 mm) at 0.5 ml/min. Elution employed a linear
gradient from 10% to 70% buffer B in buffer A over 16 minutes.
Buffers A and B contained 5% and 60% (v/v) methanol,
respectively, in 400 mM hexafluoroisopropanol, 16.3 mM trieth-
ylamine, pH 8.0. Detection was performed on a Waters LCT
Premier XE (Micromass) electrospray ionisation mass spectrom-
eter connected to the HPLC system (HP1050 Series) in negative
ion mode.
Supporting Information
Figure S1 In silico analysis of the ALKBH5 promoter.
Analysis of the ALKBH5 promoter and conservation of identified
putative transcription factor binding sites. Both identified putative
HIF binding sites are highly conserved.
(TIF)
Figure S2 No apparent activity of recombinant ALKBH5
on methylated oligonucleotides. Single-stranded DNA
oligonucleotides containing 1-methyladenine (1meA), 3-methyl-
cytosine (3meC), 5-methylcytosine (5meC), 1-methylguanine
(1meG) and 3-methylthymine (3meT) were incubated overnight
with recombinant ALKBH5 and oligonucleotides were analyzed
by ion-pairing LCMS. No modification is observed on any of the
oligonucleotides.
(TIF)
Figure S3 No apparent role for ALKBH5 in the DNA
damage response. U2OS cells treated with either scrambled or
ALKBH5 siRNA were exposed to the periods of hypoxia and
reoxygenation indicated and stained for either cH2AX (A) or
53BP1 (B). In each case the number of cells with .10 nuclear foci
were scored. In each condition a minimum of 100 cells were
scored. Doxorubicin (2 mM) was used a positive control for DNA
damage induction. (C) U2OS cells were treated with scrambled
(control) or ALKBH5 siRNA and exposed to 0.02% O2 for the
times indicated. Cells were then returned to normal incubation
conditions and colonies allowed to form. (D) U2OS cells were
treated with scrambled (control) or ALKBH5 siRNA and exposed
to 2.0% O2 for 24 hours. 30 minutes prior to reoxygenation cells
were irradiated as indicated. Cells were then allowed to form
colonies and counted.
(JPG)
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